dos Programas de Pós-graduação em Antropologia Social e . treinou a maior parte dos médicos que foram professores de farmacologia; um aluno seu, John. Antivirais/farmacologia Vírus da Encefalite de St. Louis/efeitos dos fármacos Tiazóis/farmacologia Tiossemicarbazonas/farmacologia Vírus da Febre. Assunto(s): Antivirais/farmacologia Vírus da Influenza A/efeitos dos fármacos Vírus da Influenza B/efeitos dos fármacos Ácido Micofenólico/farmacologia.

Author: Gardara Samujora
Country: Trinidad & Tobago
Language: English (Spanish)
Genre: Photos
Published (Last): 11 March 2008
Pages: 170
PDF File Size: 8.67 Mb
ePub File Size: 2.52 Mb
ISBN: 920-4-91510-519-3
Downloads: 23198
Price: Free* [*Free Regsitration Required]
Uploader: Brashicage

Listar documentos Limpar lista. Nenhum documento selecionado Para: The development of new antiviral drugs based on nucleic acids is under scrutiny. An important problem in this aspect is to find the most vulnerable conservative regions in the viral genome as targets for the action of these agents.

Another challenge is the development of an efficient system for their delivery into cells. Within the negative strand fsrmacologia each of the studied strains, the efficiency of DNA fragments increased in the direction of its 3′-end. Thus, the DNA fragment aimed at the 3′-noncoding region of – RNA was the most efficient and inhibited the reproduction of different IAV subtypes by orders of magnitude.

Some patterns of localization of the most vulnerable regions in IAV segment 5 for the action of DNA-based drugs were found. Influenza A virus IAV carmacologia seasonal epidemics of respiratory illness that can cause mild to severe illness and potentially death.

Farmacologia dos antivirais.ppt

Antiviral drugs are an important countermeasure against IAV; however, drug resistance has developed, thus new therapeutic approaches are being sought.

Previously, we demonstrated the antiviral activity of a novel nuclear export inhibitor drug, verdinexor, to reduce influenza replication in vitro antivirqis pulmonary virus burden in mice. In this study, in vivo effic mais acy of verdinexor was further evaluated in two animal models or influenza virus infection, mice and ferrets.

In mice, verdinexor was efficacious to limit virus shedding, reduce pulmonary pro-inflammatory cytokine expression, and moderate leukocyte infiltration into the bronchoalveolar space. Similarly, verdinexor-treated ferrets had reduced lung pathology, virus burden, and inflammatory cytokine expression in the nasal wash exudate.

These findings support the anti-viral efficacy of verdinexor, and warrant its development as a novel antiviral therapeutic for influenza infection. Mycoplasma hyopneumoniae does not affect the interferon-related anti-viral response but predisposes the pig to a higher level of inflammation following swine influenza virus infection.

In pigs, influenza A viruses and Mycoplasma hyopneumoniae Mhp are major farmscologia to the porcine respiratory disease complex. Pre-infection with Mhp was previously shown experimentally to exacerbate the clinical outcomes of H1N1 infection during the first week after virus inoculation.

In order to better understand the far,acologia between these pathogens, we aimed to assess very early responses at 5, 24 and 48 h after H1N1 infection in farmacologja pre-infected or not with Mhp.

Clinical sign mais s and macroscopic lung lesions were similar in both infected groups at early times post-H1N1 infection; and Mhp pre-infection affected neither the influenza virus replication nor the IFN-induced antiviral responses in the lung. Thus, it seems it is this marked inflammatory state that would play a role in farmaco,ogia the clinical signs subsequent to H1N1 infection. A Potential New Human Antiviral. Defective interfering DI viruses arise during the replication of influenza A virus and contain a non-infective version of the genome that is able to interfere with the production of infectious virus.

In this study we hypothesise that a cloned DI influenza A virus RNA may prevent infection of human respiratory epithelial cells with infection by influenza A. However, evidence that DI influenza viruses are active in cells of the human respiratory tract is lacking. The Influenza Virus Polymerase Complex: Stevaert, Annelies; Naesens, Lieve. Influenza viruses cause seasonal epidemics and pandemic outbreaks associated with significant morbidity and mortality, and a huge cost.


Since resistance to the existing anti-influenza drugs is rising, innovative inhibitors with a different mode of action are urgently needed. The influenza polymerase complex is widely recognized as a key drug target, given its critical role in virus replication and high degree of conservation among influenza A of human or zoonotic origin and B viruses.

We mais here review the major progress that has been made in recent years in unravelling the structure and functions of this protein complex, enabling structure-aided drug design toward the core regions of the PA endonuclease, PB1 polymerase, or cap-binding PB2 subunit.

Alternatively, inhibitors may target a protein-protein interaction site, a cellular factor involved in viral RNA synthesis, the viral RNA itself, or the nucleoprotein component of the viral ribonucleoprotein. The latest advances made for these diverse pharmacological targets have yielded agents in advanced i. Influenza A virus IAV is a human respiratory pathogen that causes seasonal epidemics and farmacologai global pandemics with devastating levels of morbidity and mortality.

Currently ods treatments against influenza are losing effectiveness, as new viral strains are often refractory to conventional treatments. Thus, there is an urgent need to find new therapeutic targets with which to develop novel antiviral drugs. The common strategy to discover new drug targets and antivirals is high t mais hroughput screening.

However, most current screenings for IAV rely on the engineered virus carrying a reporter, which prevents the application to newly emerging wild type flu viruses, such as pandemic H1N1 flu. A pilot compound screening identified a small molecule that inhibited IAV infection. Taken together, our method represents a reliable and convenient high throughput assay for screening novel host factors and antiviral compounds.

Preserved antiviral adaptive immunity following polyclonal antibody immunotherapy for severe murine influenza infection. Passive immunotherapy may have particular benefits for the treatment of severe influenza infection in at-risk populations, however little is known of the impact of passive immunotherapy on the formation of memory responses to the virus.

Ideally, passive immunotherapy should attenuate the severity of infection while still allowing the formation of adaptive responses to confer protection from future exposure. In this study, we sought to determine if administration of influenza-specific ovine mais polyclonal antibodies could inhibit adaptive immune responses in a murine model of lethal influenza infection. Ovine polyclonal antibodies generated against recombinant PR8 H1N1 hemagglutinin exhibited potent prophylactic capacity and reduced lethality in an established influenza infection, particularly when administered intranasally.

Surviving mice were vos protected against reinfection and generated normal antibody and cytotoxic T lymphocyte responses to the virus.

The longevity of ovine polyclonal antibodies was explored with a half-life of over two weeks following a single antibody administration.

These findings support the development of an ovine passive polyclonal antibody therapy for treatment of severe influenza infection which does not affect the formation of subsequent acquired immunity to the virus. Mycophenolic acid, an immunomodulator, has potent and broad-spectrum in vitro antiviral activity against pandemic, seasonal and avian influenza viruses affecting humans. Dod have been farmacolofia to improve the outcome of severe pneumonia.

This study further investigated the antiviral activity and mechanism of action of MPA against contemporary clinical isolates of influenza A and B viruses. The antiviral effect of MPA was completely reverted by guanosine supplementation.

Influenza is a serious public health concern worldwide, as it causes farmacologis morbidity and mortality. The emergence of drug-resistant viral strains requires new approaches for the treatment of influenza. In this study, Rubus coreanus seed RCS that is left over from the production of wine or juice was found to show antiviral activities against influenza type A and B viruses.

Using the time-of-addition plaque assay, viral replication was almost completely abolished by simultaneous treat mais ment with the RCS fraction of less than a 1-kDa molecular weight RCSF1.


One of the polyphenols derived from RCSF1, gallic acid GAidentified by liquid chromatography-tandem mass spectrometry, showed inhibitory effects against both influenza type A and B viruses, albeit at relatively high concentrations.

RCSF1 was bound to hemagglutinin protein, inhibited hemagglutination significantly and disrupted viral particles, whereas GA was found to only disrupt the viral particles by using transmission electron microscopy.

Our results demonstrate that RCSF1 and GA show potent and broad antiviral activity against influenza A and B type viruses and are promising sources of agents that target virus particles.

Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Here, we conducted a cell-based screening system to evaluate the susceptibility of influenza viruses to favipiravir. In this assay, the antiviral activity of favipiravir is determined by inhibition of virus-induced cytopathic effect, which can be measured by using a colorimetric cell proliferation assay. To demonstrate the robustness of the assay, we compared mais the favipiravir susceptibilities of neuraminidase NA inhibitor-resistant influenza A H1N1 pdm09, A H3N2A H7N9 and B viruses and their antuvirais counterparts.

Farmacologia dos – ppt carregar

No significant differences in the favipiravir susceptibilities were found between NA inhibitor-resistant and sensitive viruses.

We, then, examined the antiviral susceptibility of 57 pairs of influenza viruses isolated from patients pre- and post-administration of favipiravir in phase 3 clinical trials. This is the first report on the antiviral susceptibility of influenza viruses isolated from patients after favipiravir treatment. Antiviral activity of hydroalcoholic extract from Eupatorium perfoliatum L.

Aerial parts of Eupatorium perfoliatum have been traditionally used by American natives as a treatment for fever and infections. Also modern phytotherapy in Europe documents the use of hydroalcoholic extracts of this herbal material for the treatment of infections of the upper respiratory tract. The aim of the present study was to characterize the anti-influenza A virus IAV potential of extracts derived from the aerial parts of E.

Plaque reduction assays were used for investigation of antiviral activity. The mode of action was investigated by different incubation and treatment cycles as well as hemagglutination inhibition assays. Hydroalcoholic extracts from the aerial parts of E.

Antivirais by jose afonso on Prezi

Extracts prepared with dichloromethane and methanol were inactive. The extract blocked attachment of IAV and interfered with virus-induced hemagglutination.

Bioassay-guided fractionation and subsequent LC-MS analysis indicated that the antiviral activity might be due to polyphenolic compounds with higher molecular weights, which strongly interact with stationary phases of different chromatographic systems. These still unknown compounds with probably high molecular weight could not be isolated in the present study. A variety of different flavonoid glycosides and caffeoyl quinic acids obtained from E.

The extract appears to be a promising expansion of the currently available anti-influenza agents. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease.

We show that IAV-infected monocytes from older humans have impaired antiviral interferon production but retain intact inflammasome responses.

To understand the in vivo consequence, we used mice expressing a functional Mx gene encoding a major interferon-induced effector against IAV in humans. In Mx1-intact mice with weakened resistance due to deficiencies in Mavs and Tlr7, we f mais ound an elevated respiratory bacterial burden.

Therefore, in the context of weakened antiviral resistance, vulnerability to IAV disease is a function of caspase-dependent pathology.